DrugPatentWatch Database Preview
EXONDYS 51 Drug Profile
Which patents cover Exondys 51, and what generic alternatives are available?
This drug has one hundred and eighty-two patent family members in twenty-three countries.
The generic ingredient in EXONDYS 51 is eteplirsen. One supplier is listed for this compound. Additional details are available on the eteplirsen profile page.
Summary for EXONDYS 51
| International Patents: | 182 |
| US Patents: | 5 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Drug Prices: | see details |
| DailyMed Link: | EXONDYS 51 at DailyMed |
Pharmacology for EXONDYS 51
| Ingredient-type | Oligonucleotides, Antisense |
| Drug Class | Antisense Oligonucleotide |
US Patents and Regulatory Information for EXONDYS 51
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sarepta Theraps Inc | EXONDYS 51 | eteplirsen | SOLUTION;IV (INFUSION) | 206488-001 | Sep 19, 2016 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| Sarepta Theraps Inc | EXONDYS 51 | eteplirsen | SOLUTION;IV (INFUSION) | 206488-002 | Sep 19, 2016 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Sarepta Theraps Inc | EXONDYS 51 | eteplirsen | SOLUTION;IV (INFUSION) | 206488-001 | Sep 19, 2016 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| Sarepta Theraps Inc | EXONDYS 51 | eteplirsen | SOLUTION;IV (INFUSION) | 206488-001 | Sep 19, 2016 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Non-Orange Book US Patents for EXONDYS 51
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 8,329,668 | Antisense antiviral compound and method for treating picornavirus infection | ➤ Try a Free Trial |
| 8,232,384 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof | ➤ Try a Free Trial |
| 8,084,433 | Antisense antiviral compound and method for treating ssRNA viral infection | ➤ Try a Free Trial |
| 8,450,474 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof | ➤ Try a Free Trial |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for EXONDYS 51
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Croatia | P20160025 | ➤ Try a Free Trial |
| China | 105647921 | ➤ Try a Free Trial |
| Japan | 5600064 | ➤ Try a Free Trial |
| Canada | 2596506 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
